Literature DB >> 1356162

Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells.

S Deb1, C T Jackson, M A Subler, D W Martin.   

Abstract

Wild-type p53 has recently been shown to repress transcription from several cellular and viral promoters. Since p53 mutations are the most frequently reported genetic defects in human cancers, it becomes important to study the effects of mutations of p53 on promoter functions. We, therefore, have studied the effects of wild-type and mutant human p53 on the human proliferating-cell nuclear antigen (PCNA) promoter and on several viral promoters, including the herpes simplex virus type 1 UL9 promoter, the human cytomegalovirus major immediate-early promoter-enhancer, and the long terminal repeat promoters of Rous sarcoma virus and human T-cell lymphotropic virus type I. HeLa cells were cotransfected with a wild-type or mutant p53 expression vector and a plasmid containing a chloramphenicol acetyltransferase reporter gene under viral (or cellular) promoter control. As expected, expression of the wild-type p53 inhibited promoter function. Expression of a p53 with a mutation at any one of the four amino acid positions 175, 248, 273, or 281, however, correlated with a significant increase of the PCNA promoter activity (2- to 11-fold). The viral promoters were also activated, although to a somewhat lesser extent. We also showed that activation by a mutant p53 requires a minimal promoter containing a lone TATA box. A more significant increase (25-fold) in activation occurs when the promoter contains a binding site for the activating transcription factor or cyclic AMP response element-binding protein. Using Saos-2 cells that do not express p53, we showed that activation by a mutant p53 was a direct enhancement. The mutant forms of p53 used in this study are found in various cancer cells. The activation of PCNA by mutant p53s may indicate a way to increase cell proliferation by the mutant p53s. Thus, our data indicate a possible functional role for the mutants of p53 found in cancer cells in activating several important loci, including PCNA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356162      PMCID: PMC283665     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Differential ability of proximal and remote element pairs to cooperate in activating RNA polymerase II transcription.

Authors:  W D Wang; J D Gralla
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

2.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

Authors:  J Martinez; I Georgoff; J Martinez; A J Levine
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

3.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

4.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

5.  Evidence for interaction of different eukaryotic transcriptional activators with distinct cellular targets.

Authors:  K J Martin; J W Lillie; M R Green
Journal:  Nature       Date:  1990-07-12       Impact factor: 49.962

6.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

7.  Identification of p53 as a sequence-specific DNA-binding protein.

Authors:  S E Kern; K W Kinzler; A Bruskin; D Jarosz; P Friedman; C Prives; B Vogelstein
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

8.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

9.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.

Authors:  D Malkin; F P Li; L C Strong; J F Fraumeni; C E Nelson; D H Kim; J Kassel; M A Gryka; F Z Bischoff; M A Tainsky
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  54 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 3.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

4.  p73 function is inhibited by tumor-derived p53 mutants in mammalian cells.

Authors:  C J Di Como; C Gaiddon; C Prives
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

Authors:  K Will; G Warnecke; L Wiesmüller; W Deppert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

6.  Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.

Authors:  Heidi Sankala; Catherine Vaughan; Jing Wang; Sumitra Deb; Paul R Graves
Journal:  Arch Biochem Biophys       Date:  2011-05-20       Impact factor: 4.013

7.  Molecular analysis of p53 gene in laryngeal premalignant and malignant lesions. p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index.

Authors:  V Gorgoulis; V Zoumpourlis; G Rassidakis; A Karameris; C Barbatis; D A Spandidos; C Kittas
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.

Authors:  U P Kelavkar; K F Badr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

9.  Phosphorylation at Ser-15 and Ser-392 in mutant p53 molecules from human tumors is altered compared to wild-type p53.

Authors:  S J Ullrich; K Sakaguchi; S P Lees-Miller; M Fiscella; W E Mercer; C W Anderson; E Appella
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication.

Authors:  L Duan; I Ozaki; J W Oakes; J P Taylor; K Khalili; R J Pomerantz
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.